Hikma Pharmaceuticals: Difference between revisions
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
location = Headquartered in [[London]], [[United Kingdom|UK]] | |
location = Headquartered in [[London]], [[United Kingdom|UK]] | |
||
key_people = [[Samih Darwazah]] [[Chairman|Chairman]]<br/> [[Said Darwazah]] [[chief executive officer|CEO]]<br />[[Taghreed Al-Shunnar]] [[Vice president|VP]]<br/>| |
key_people = [[Samih Darwazah]] [[Chairman|Chairman]]<br/> [[Said Darwazah]] [[chief executive officer|CEO]]<br />[[Taghreed Al-Shunnar]] [[Vice president|VP]]<br/>| |
||
num_employees = |
num_employees = 2,000 (2006) | |
||
industry = [[Pharmaceuticals]]| |
industry = [[Pharmaceuticals]]| |
||
products = [[Amoclan]]<br/>[[Prograf]]<br />[[Suprax]]<br />[[#Products|See complete products listing.]] | |
products = [[Amoclan]]<br/>[[Prograf]]<br />[[Suprax]]<br />[[#Products|See complete products listing.]] | |
||
revenue = $317 million (2006) | |
revenue = $317 million (2006) | |
||
homepage = [http://www.hikma.com/ www.hikma.com]|}} |
homepage = [http://www.hikma.com/ www.hikma.com]|}} |
||
'''Hikma Pharmaceuticals''' ({{LSE|HIK}}) is a [[multinational corporation|multinational]] [[pharmaceutical company]] based in [[London, United Kingdom]] that manufactures branded/non-branded[[generic drug|generic]] and in-licensed products. The firm was founded in [[Amman, Jordan|Amman]], [[Jordan]] in 1978. In August 1996, Hikma Pharmaceuticals became the first Arab company to export pharmaceutical products to the United States<ref>http://www.kinghussein.gov.jo/economy9.html#Industry</ref>. |
'''Hikma Pharmaceuticals''' ({{LSE|HIK}}) is a [[multinational corporation|multinational]] [[pharmaceutical company]] based in [[London, United Kingdom]] that manufactures branded/non-branded [[generic drug|generic]] and in-licensed pharmaceutical products. The firm was founded in [[Amman, Jordan|Amman]], [[Jordan]] in 1978. In August 1996, Hikma Pharmaceuticals became the first Arab company to export pharmaceutical products to the United States<ref>http://www.kinghussein.gov.jo/economy9.html#Industry</ref>. |
||
Hikma has manufacturing facilities located in six countries: USA, Portugal, Italy, Jordan, Saudi Arabia and Algeria. |
Hikma has manufacturing facilities located in six countries: USA, Portugal, Italy, Jordan, Saudi Arabia and Algeria. |
||
==Acquisitions== |
|||
* Jazeera Pharmaceutical [[KSA]]. |
|||
* Instituto Biochimico Pavese Pharma [[Pavia, Italy]]. |
|||
* Ribosepharm [[Germany]]. |
|||
* Thymoorgan [[Germany]]. |
|||
==Notes== |
==Notes== |
||
Revision as of 08:32, 13 July 2007
| File:Hikma logo2.gif | |
| Company type | Public (LSE: HIK) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | Amman, Jordan (1978) |
| Founder | Samih Darwazah  |
| Headquarters | Headquartered in London, UK |
Key people | Samih Darwazah Chairman Said Darwazah CEO Taghreed Al-Shunnar VP |
| Products | Amoclan Prograf Suprax See complete products listing. |
| Revenue | $317 million (2006) |
Number of employees | 2,000 (2006) |
| Website | www.hikma.com |
Hikma Pharmaceuticals (LSE: HIK) is a multinational pharmaceutical company based in London, United Kingdom that manufactures branded/non-branded generic and in-licensed pharmaceutical products. The firm was founded in Amman, Jordan in 1978. In August 1996, Hikma Pharmaceuticals became the first Arab company to export pharmaceutical products to the United States[1]. Hikma has manufacturing facilities located in six countries: USA, Portugal, Italy, Jordan, Saudi Arabia and Algeria.
Acquisitions
- Jazeera Pharmaceutical KSA.
- Instituto Biochimico Pavese Pharma Pavia, Italy.
- Ribosepharm Germany.
- Thymoorgan Germany.
Notes
External links
- Hikma Pharmaceuticals PLC Website - Official site
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
 | This Jordan-related article is a stub. You can help Wikipedia by expanding it. |
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |